NEWS HIGHLIGHTSMedia Articles Related to Theo-24 (Theophylline)
Asthma Increases Risk for Periodontitis Source: Medscape Allergy & Clinical Immunology Headlines [2017.09.25] People with asthma should pay particularly close attention to their oral health after research found a strong link between the condition and gum disease. WebMD Health News
Could Pests, Dust Lower Kids' Odds for Asthma? Source: MedicineNet Allergy Specialty [2017.09.22] Title: Could Pests, Dust Lower Kids' Odds for Asthma? Category: Health News Created: 9/21/2017 12:00:00 AM Last Editorial Review: 9/22/2017 12:00:00 AM
Asthma Drug Tied to Nightmares, Depression Source: MedicineNet Allergy Specialty [2017.09.22] Title: Asthma Drug Tied to Nightmares, Depression Category: Health News Created: 9/21/2017 12:00:00 AM Last Editorial Review: 9/22/2017 12:00:00 AM
Kids' Colds Linked to Asthma, Lung Problems Later Source: MedicineNet Adenoids and Tonsils Specialty [2017.09.20] Title: Kids' Colds Linked to Asthma, Lung Problems Later Category: Health News Created: 9/19/2017 12:00:00 AM Last Editorial Review: 9/20/2017 12:00:00 AM
Asthma Quiz: Test Your Medical IQ Source: MedicineNet Asthma Complexities Specialty [2017.09.19] Title: Asthma Quiz: Test Your Medical IQ Category: MedicineNet Quiz Created: 6/3/2011 4:21:00 PM Last Editorial Review: 9/19/2017 6:36:12 PM
Published Studies Related to Theo-24 (Theophylline)
The protective effect of theophyline in cisplatin nephrotoxicity. [2014] Cisplatin is a potent and a major anti-neoplastic drug in the treatment of a
broad spectrum of malignancies. However, its clinical use is limited by renal
tubular dysfunction that occurs in a significant percent of patients...
Beneficial effects of theophylline infusions in surgical patients with intra-abdominal hypertension. [2011.08] BACKGROUND: Intra-abdominal hypertension (IAH) can cause high mortality. Recently, we found that IAH was associated with increased serum levels of adenosine and interleukin 10. Our present "hypothesis-generated study" was based on the above mentioned results... CONCLUSIONS: Adenosine receptor antagonism with T following IAH diagnosis resulted in markedly reduced mortality in patients with moderated IAH (<20 mmHg). Theophylline-associated mortality reduction may be related to improved renal perfusion and improved MAP, presumably caused by adenosine receptor blockade. Because this study was not a randomized controlled study, these compelling observations require further multicentric clinical confirmation.
Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. [2011.07] OBJECTIVE: To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2... CONCLUSIONS: Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans. Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed.
Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.11] Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...
Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.09.29] Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...
Clinical Trials Related to Theo-24 (Theophylline)
Bioavailability of Two Sustained-release Theophylline Products in Healthy Males [Completed]
Study to compare the bioavailability of 350 mg Bronchoretard® - a sustained-release
theophylline (anhydrous) product with respect to the reference product, Theo Dur® 300 mg
theophylline anhydrous (sustained-release product) by comparing the rate and extent of
absorption of theophylline based on both single and multiple-dose profiles.
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline [Recruiting]
This study is to determine the use of theophylline in patients with NSCLC and advanced solid
malignancies and whether treatment with theophylline will help lower or diminish the side
effect of diarrhea in patients taking erlotinib. Patients will be enrolled in one of two
parts of the study to verify the lowest dose of theophylline that is effective and the
highest dose of erlotinib that can be tolerated with theophylline. If this study shows that
theophylline is able to inhibit erlotinib induced diarrhea, it will help demonstrate that
patients using the tyrosine kinase inhibitor (TKIs), erlotinib, can use it effectively at
higher doses without experiencing severe diarrhea.
Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning [Recruiting]
The purpose of this study is to evaluate the effect of primary tumor resection on the
metabolic activity of metastases in patients with a colorectal primary tumor and synchronous
liver metastases by positron emission tomography (PET) with 2-deoxy-2-fluoro[18F]-D-glucose
(FDG-PET) scanning.
Optical Detection of Malignancy During Percutaneous Interventions [Recruiting]
Investigation of application possibilities of optical spectroscopy within the field of
oncology. Optical spectroscopy enables the possibility to specifically differentiate between
different (human) tissues. The hypothesis is that incorporation of this technique into
existing medical devices (e. g. biopsy needle) would enlarge the accuracy and reliability of
these devices. The purpose is to improve and speed up the diagnostics and therapy of the
malignancies.
Natural History of Noncirrhotic Portal Hypertension [Recruiting]
Background:
- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure
in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
Many people may not even know that they have a liver disease. There are no specific
treatments for NCPH.
Objectives:
- To learn more about how NCPH develops over time.
Eligibility:
- People age 12 and older who have NCPH or are at risk for getting it. In the past year,
they cannot have had other types of liver disease that typically result in cirrhosis, liver
cancer, or active substance abuse.
Design:
- Participants will have 2 screening visits.
- Visit 1: to see if they have or may develop NCPH.
- Medical history
- Physical exam
- Urine and stool studies
- Abdominal ultrasound
- Fibroscan. Sound waves measure liver stiffness.
< TAB> - Visit 2:
- Blood tests
- Abdominal MRI
- Echocardiogram
- Questionnaire
- Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This
is done with a small tube inserted in a neck vein.
- They may have a liver biopsy.
- All participants will visit the clinic every 6 months for a history, physical exam, and
blood tests. They will also repeat some of the screening tests yearly.
- Participants with NCPH will also have:
- Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and
stomach.
- At least every 2 years: Esophagogastroduodenoscopy.
- At least every 4 years: testing including HVPG measurements and liver biopsy.
- Participants without NCPH will also have:
- Liver biopsy and HVPG measurements to see if they have NCPH.
- Every 2 years: abdominal MRI and stool studies.
- The study will last indefinitely.
|